These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38915460)

  • 21. Design and synthesis of a novel class of PDE4 inhibitors with antioxidant properties as bifunctional agents for the potential treatment of COPD.
    Wang Y; Wang H; Yang G; Hao Q; Yang K; Shen H; Wang Y; Wang J
    Eur J Med Chem; 2023 Aug; 256():115374. PubMed ID: 37150057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis.
    Bäumer W; Hoppmann J; Rundfeldt C; Kietzmann M
    Inflamm Allergy Drug Targets; 2007 Mar; 6(1):17-26. PubMed ID: 17352685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.
    Schafer PH; Truzzi F; Parton A; Wu L; Kosek J; Zhang LH; Horan G; Saltari A; Quadri M; Lotti R; Marconi A; Pincelli C
    Cell Signal; 2016 Jul; 28(7):753-63. PubMed ID: 26806620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atopic dermatitis: a review of topical nonsteroid therapy.
    Papier A; Strowd LC
    Drugs Context; 2018; 7():212521. PubMed ID: 29632548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-inflammatory effects of a novel phosphodiesterase-4 inhibitor, AA6216, in mouse dermatitis models.
    Kubota-Ishida N; Matsuhira T; Kaji C; Kikuchi C; Tabata Y
    Eur J Pharmacol; 2021 Sep; 906():174258. PubMed ID: 34139195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease.
    Facchinetti F; Civelli M; Singh D; Papi A; Emirova A; Govoni M
    Front Pharmacol; 2021; 12():740803. PubMed ID: 34887752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases.
    Phillips JE
    Front Pharmacol; 2020; 11():259. PubMed ID: 32226383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.
    Dastidar SG; Rajagopal D; Ray A
    Curr Opin Investig Drugs; 2007 May; 8(5):364-72. PubMed ID: 17520865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphodiesterase 4 inhibitors.
    Zebda R; Paller AS
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S43-S52. PubMed ID: 29248522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases.
    Schett G; Sloan VS; Stevens RM; Schafer P
    Ther Adv Musculoskelet Dis; 2010 Oct; 2(5):271-8. PubMed ID: 22870453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is PDE4 too difficult a drug target?
    Higgs G
    Curr Opin Investig Drugs; 2010 May; 11(5):495-8. PubMed ID: 20419594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition.
    Guttman-Yassky E; Hanifin JM; Boguniewicz M; Wollenberg A; Bissonnette R; Purohit V; Kilty I; Tallman AM; Zielinski MA
    Exp Dermatol; 2019 Jan; 28(1):3-10. PubMed ID: 30332502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis.
    Herrmann FE; Hesslinger C; Wollin L; Nickolaus P
    Front Pharmacol; 2022; 13():838449. PubMed ID: 35517783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.
    Konrad FM; Bury A; Schick MA; Ngamsri KC; Reutershan J
    PLoS One; 2015; 10(4):e0121725. PubMed ID: 25909327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TAS-203, an oral phosphodiesterase 4 inhibitor, exerts anti-inflammatory activities in a rat airway inflammation model.
    Demizu S; Asaka N; Kawahara H; Sasaki E
    Eur J Pharmacol; 2019 Apr; 849():22-29. PubMed ID: 30716315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-analysis.
    Yang H; Wang J; Zhang X; Zhang Y; Qin ZL; Wang H; Luo XY
    JAMA Dermatol; 2019 May; 155(5):585-593. PubMed ID: 30916723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyperresponsiveness in guinea pigs.
    Mokry J; Urbanova A; Medvedova I; Kertys M; Mikolka P; Kosutova P; Mokra D
    J Physiol Pharmacol; 2017 Oct; 68(5):721-730. PubMed ID: 29375047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current insights on clinical efficacy of roflumilast for treatment of COPD, asthma and ACOS.
    Bodkhe S; Nikam M; Sherje AP; Khan T; Suvarna V; Patel K
    Int Immunopharmacol; 2020 Nov; 88():106906. PubMed ID: 33182057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective Inhibition of Phosphodiesterases 4A, B, C and D Isoforms in Chronic Respiratory Diseases: Current and Future Evidences.
    Contreras S; Milara J; Morcillo E; Cortijo J
    Curr Pharm Des; 2017; 23(14):2073-2083. PubMed ID: 28201975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.